BioInvent International ABShs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.03.19	BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors (PR Newswire)
26.03.19	BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors (PR Newswire)
21.03.19	BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors (PR Newswire)
21.03.19	BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors (PR Newswire)
19.03.19	Notice to Annual General Meeting in BioInvent International AB (PR Newswire)
19.03.19	Notice to Annual General Meeting in BioInvent International AB (PR Newswire)
12.03.19	BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs (PR Newswire)
12.03.19	BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs (PR Newswire)
25.02.19	Notice of Extraordinary General Meeting in BioInvent International AB (PR Newswire)
25.02.19	Notice of Extraordinary General Meeting in BioInvent International AB (PR Newswire)
25.02.19	BioInvent Financial Statement January 1 - December 31, 2018 (PR Newswire)
25.02.19	BioInvent Financial Statement January 1 - December 31, 2018 (PR Newswire)
05.02.19	BioInvent CSO to Present F.I.R.S.T.™ Discovery Platform at SLAS2019 (PR Newswire)
05.02.19	BioInvent CSO to Present F.I.R.S.T.™ Discovery Platform at SLAS2019 (PR Newswire)
30.01.19	BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma (PR Newswire)
30.01.19	BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma (PR Newswire)
20.11.18	BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company (PR Newswire)
20.11.18	BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company (PR Newswire)
13.11.18	BioInvent Announces Publication of Data in Leading Cancer Journal Immunity (PR Newswire)
13.11.18	BioInvent Announces Publication of Data in Leading Cancer Journal Immunity (PR Newswire)
07.11.18	Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-development of a Next-generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody (PR Newswire)
07.11.18	Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-development of a Next-generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody (PR Newswire)
17.10.18	BioInvent Embarks on Intensive Investor Meeting Program in the U.S., Europe, and Israel, and Posts Updated Presentation on Corporate Website (PR Newswire)
17.10.18	BioInvent Embarks on Intensive Investor Meeting Program in the U.S., Europe, and Israel, and Posts Updated Presentation on Corporate Website (PR Newswire)
16.10.18	BioInvent to Expand Pipeline With New Development Programs in Solid Cancer (PR Newswire)
16.10.18	BioInvent to Expand Pipeline With New Development Programs in Solid Cancer (PR Newswire)
08.11.16	BioInvent Reports Clinical Hold on BI-505 Phase II Study (Businesswire)
25.10.16	BioInvent Interim Report 1 January – 30 September 2016 (Businesswire)
19.09.16	BioInvent Expands Patent Approvals for Its Lead Clinical Immuno-Oncology Programme in Multiple Myeloma, BI-505 (Businesswire)
29.08.16	BioInvent Extends Manufacturing Services Contract with Major Global Pharmaceutical Client; Expects to Generate Approximately SEK 8 Million in Revenue (Businesswire)
26.07.16	BioInvent Interim Report 1 January – 30 June 2016 (Businesswire)
08.07.16	BioInvent Enter Process Development and Manufacturing Collaboration with Alligator (Businesswire)
12.05.16	BioInvent: Resolution at BioInvent’s Annual General Meeting 2016 (Businesswire)
06.05.16	BioInvent: BioInvent’s Board Director Dharminder Chahal increases his shareholding in the company (Businesswire)
02.05.16	BioInvent, Oncurious NV and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma (Businesswire)
29.04.16	BioInvent: Change in the number of shares and votes in BioInvent International AB (Businesswire)
26.04.16	BioInvent Interim Report 1 January – 31 March 2016 (Businesswire)
15.04.16	BioInvent: BioInvent’s Rights Issue Completed (Businesswire)
12.04.16	Annual General Meeting in BioInvent International AB (Businesswire)
23.03.16	BioInvent Publishes Prospectus (Businesswire)
23.03.16	BioInvent: Annual Report 2015 (Businesswire)
23.03.16	BioInvent: Annual Report 2015 (Businesswire)
18.03.16	Resolutions of the Extraordinary General Meeting of BioInvent (Businesswire)
16.03.16	BioInvent is granted a patent in Europe for the immune-oncology antibody BI-505 (Businesswire)
15.03.16	BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 (Businesswire)
29.02.16	BioInvent Receives €2 Million Milestone Payment from Daiichi Sankyo for Licensed N-CoDeR® Antibody Progressing into Phase I Clinical Trial (Businesswire)
17.02.16	BioInvent Financial Statement 1 January – 31 December 2015 (Businesswire)
17.02.16	Notice of Extraordinary General Meeting in BioInvent International AB (Businesswire)
16.02.16	BioInvent issues private placement to US-based healthcare investor Omega Funds in parallel to offering a fully guaranteed rights issue (Businesswire)
07.01.16	BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu BioInvent International ABShs

Aktien Top/Flop

Meistgelesene Nachrichten